pentetic acid has been researched along with Multiple Sclerosis in 73 studies
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI)." | 9.07 | A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. ( Andreula, C; Bastianello, S; Bozzao, A; D'Andrea, F; Gallucci, M; Gasperini, C; Millefiorini, E; Morino, S; Pozzilli, C; Trojano, M, 1994) |
| "Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI." | 7.69 | Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. ( Barkhof, F; Frequin, ST; Hommes, OR; Nauta, JJ; Scheltens, P; Tas, MW; Valk, J, 1994) |
| "Magnetic resonance imaging detects blood-brain barrier disruption after gadolinium-DTPA enhancement of central nervous system lesions of multiple sclerosis." | 7.68 | Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig. ( Grant, EA; Karlik, SJ; Lee, D; Noseworthy, JH, 1993) |
| "In a prospective study, we compared the number of gadolinium-DTPA (Gd-DTPA) enhancing lesions on MRI with the CSF and clinical findings before and after a total of 20 courses of high-dose intravenous methylprednisolone in relapsing multiple sclerosis patients." | 7.68 | A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. ( Barkhof, F; Frequin, ST; Hommes, OR; Lamers, K; Scheltens, P; Valk, J; van Geel, WJ, 1992) |
| "Ten patients with relapsing-remitting multiple sclerosis have been studied by serial gadolinium-pentetic acid magnetic resonance imaging (MRI) every 14 days for 3 months." | 7.68 | Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. ( Capra, R; Chiesa, A; Gasparotti, R; Marcianò, N; Vignolo, LA, 1992) |
| "In 12 patients with definite multiple sclerosis who received a total of 21 courses of high-dose (1 gram daily for 10 consecutive days) intravenous methylprednisolone, we performed MRI of the brain with and without gadolinium-DTPA before and after treatment." | 7.68 | Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. ( Barkhof, F; Hommes, OR; Scheltens, P; Valk, J, 1991) |
| "We performed 15 dynamic gadolinium-DTPA (Gd-DTPA)-enhanced MRI studies in 8 patients with relapsing and remitting multiple sclerosis; 7 were follow-up studies." | 7.68 | Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. ( du Boulay, EP; Kendall, BE; Kermode, AG; Kingsley, DP; MacManus, DG; McDonald, WI; Moseley, IF; Rudge, P; Thompson, AJ; Tofts, PS, 1990) |
| "We performed serial baseline and gadolinium (Gd)-DTPA-enhanced MRI in 4 patients with definite multiple sclerosis." | 7.68 | Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. ( Bastianello, S; Bernardi, S; Bozzao, L; Buttinelli, C; Fantozzi, LM; Fieschi, C; Pozzilli, C, 1990) |
| "We enrolled 11 patients with secondary progressive MS in a randomized single-masked cross-over study of plasma exchange (PE) in combination with azathioprine 2 mg/kg." | 6.68 | Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. ( Christiansen, P; Jensen, CV; Nordenbo, A; Ravnborg, M; Schreiber, K; Szpirt, W; Sørensen, PS; Wanscher, B, 1996) |
| "Gadolinium DTPA is a paramagnetic contrast agent that does not cross an intact blood-brain barrier." | 5.27 | Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. ( Atlas, SW; Galetta, S; Gonzalez-Scarano, F; Grossman, RI; Silberberg, DH, 1987) |
| "We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI)." | 5.07 | A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. ( Andreula, C; Bastianello, S; Bozzao, A; D'Andrea, F; Gallucci, M; Gasperini, C; Millefiorini, E; Morino, S; Pozzilli, C; Trojano, M, 1994) |
| "The central nervous system lesions of multiple sclerosis (MS) can be detected by magnetic resonance imaging (MRI) and the initial perivascular inflammatory component is distinguished by the presence of gadolinium enhancement." | 3.69 | Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. ( Clayton, D; Compston, A; Hale, G; Miller, D; Moreau, T; Moseley, I; Scolding, N; Thorpe, J; Waldmann, H; Wing, M, 1994) |
| "Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI." | 3.69 | Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. ( Barkhof, F; Frequin, ST; Hommes, OR; Nauta, JJ; Scheltens, P; Tas, MW; Valk, J, 1994) |
| "Long TR and gadolinium enhanced spin echo brain MRI was performed weekly for three months in three patients with relapsing-remitting or secondary progressive multiple sclerosis." | 3.69 | A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. ( Gawne-Cain, M; Hodgson, T; Lai, M; MacManus, D; McDonald, WI; Miller, DH; Thompson, AJ; Webb, S, 1996) |
| "We measured soluble intercellular adhesion molecule-1 (sICAM-1) in the serum and cerebrospinal fluid (CSF) of 35 clinically active relapsing-remitting (RR) multiple sclerosis (MS) patients who underwent both lumbar puncture and gadopentetate dimeglumine (Gd-DTPA)-enhanced MRI within an interval of 1 week, and of 30 neurological controls of whom 17 had noninflammatory neurologic diseases (NIND), 8 bacterial meningitis (BM), and 5 AIDS dementia complex (ADC)." | 3.69 | Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. ( Avolio, C; Calò, A; De Robertis, F; Defazio, G; Livrea, P; Manzari, C; Simone, IL; Trojano, M, 1996) |
| "Magnetic resonance imaging detects blood-brain barrier disruption after gadolinium-DTPA enhancement of central nervous system lesions of multiple sclerosis." | 3.68 | Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig. ( Grant, EA; Karlik, SJ; Lee, D; Noseworthy, JH, 1993) |
| "It is now well established that clinically stable patients with relapsing-remitting multiple sclerosis have ongoing disease activity when evaluated by serial gadolinium-enhanced (Gd-DTPA) magnetic resonance imaging (MRI) scans." | 3.68 | Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. ( Albert, PS; Armstrong, M; Frank, JA; Maloni, H; Martin, R; McFarland, HF; McFarlin, DE; Smith, ME; Stone, LA, 1993) |
| "In a prospective study, we compared the number of gadolinium-DTPA (Gd-DTPA) enhancing lesions on MRI with the CSF and clinical findings before and after a total of 20 courses of high-dose intravenous methylprednisolone in relapsing multiple sclerosis patients." | 3.68 | A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. ( Barkhof, F; Frequin, ST; Hommes, OR; Lamers, K; Scheltens, P; Valk, J; van Geel, WJ, 1992) |
| "Ten patients with relapsing-remitting multiple sclerosis have been studied by serial gadolinium-pentetic acid magnetic resonance imaging (MRI) every 14 days for 3 months." | 3.68 | Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. ( Capra, R; Chiesa, A; Gasparotti, R; Marcianò, N; Vignolo, LA, 1992) |
| "In 12 patients with definite multiple sclerosis who received a total of 21 courses of high-dose (1 gram daily for 10 consecutive days) intravenous methylprednisolone, we performed MRI of the brain with and without gadolinium-DTPA before and after treatment." | 3.68 | Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. ( Barkhof, F; Hommes, OR; Scheltens, P; Valk, J, 1991) |
| "We performed 15 dynamic gadolinium-DTPA (Gd-DTPA)-enhanced MRI studies in 8 patients with relapsing and remitting multiple sclerosis; 7 were follow-up studies." | 3.68 | Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. ( du Boulay, EP; Kendall, BE; Kermode, AG; Kingsley, DP; MacManus, DG; McDonald, WI; Moseley, IF; Rudge, P; Thompson, AJ; Tofts, PS, 1990) |
| "We performed serial baseline and gadolinium (Gd)-DTPA-enhanced MRI in 4 patients with definite multiple sclerosis." | 3.68 | Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. ( Bastianello, S; Bernardi, S; Bozzao, L; Buttinelli, C; Fantozzi, LM; Fieschi, C; Pozzilli, C, 1990) |
| "Thirteen patients with definite multiple sclerosis (MS), studied 16-24 months previously with magnetic resonance (MR) imaging with and without enhancement by intravenously administered gadolinium diethylenetriaminepentaacetic acid (DTPA) dimeglumine, were reexamined with a similar protocol." | 3.67 | Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. ( Braffman, BH; Brorson, JR; Goldberg, HI; Gonzalez-Scarano, F; Grossman, RI; Silberberg, DH, 1988) |
| "We enrolled 11 patients with secondary progressive MS in a randomized single-masked cross-over study of plasma exchange (PE) in combination with azathioprine 2 mg/kg." | 2.68 | Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. ( Christiansen, P; Jensen, CV; Nordenbo, A; Ravnborg, M; Schreiber, K; Szpirt, W; Sørensen, PS; Wanscher, B, 1996) |
| "Multiple sclerosis is a chronic demyelinating disease." | 2.39 | [Magnetic resonance imaging of disseminated sclerosis]. ( Christiansen, AP; Henriksen, O; Larsson, HB; Wanscher, B, 1994) |
| "After the episode of acute transverse myelopathy, in 4 of 8 patients in group A and in 4 of 5 patients with normal spinal MR but abnormal brain MR findings clinical signs of multiple sclerosis developed." | 1.29 | Acute transverse myelopathy: spinal and cranial MR study with clinical follow-up. ( Baratti, C; Campi, A; Comi, G; Filippi, M; Martinelli, V; Rovaris, M; Scotti, G, 1995) |
| "Balo's concentric sclerosis was diagnosed antemortem in 2 patients, by magnetic resonance (MR) imaging showing striking concentric alternating rings in 1 patient and by characteristic histopathological features in the other." | 1.29 | Balo's concentric sclerosis. Report of two patients with magnetic resonance imaging follow-up. ( Bolay, H; Karabudak, R; Onol, B; Saribaş, O; Selekler, K; Tacal, T, 1996) |
| "Gadolinium DTPA is a paramagnetic contrast agent that does not cross an intact blood-brain barrier." | 1.27 | Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. ( Atlas, SW; Galetta, S; Gonzalez-Scarano, F; Grossman, RI; Silberberg, DH, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (10.96) | 18.7374 |
| 1990's | 65 (89.04) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartolini, S | 1 |
| Inzitari, D | 1 |
| Castagnoli, A | 1 |
| Amaducci, L | 1 |
| Guttmann, CR | 1 |
| Ahn, SS | 1 |
| Hsu, L | 1 |
| Kikinis, R | 1 |
| Jolesz, FA | 1 |
| Nomura, M | 1 |
| Suzumura, A | 1 |
| Anno, H | 1 |
| Miyata, E | 1 |
| Koga, S | 1 |
| Yamamoto, H | 1 |
| Larsson, HB | 4 |
| Tas, MW | 4 |
| Barkhol, F | 1 |
| van Walderveen, MA | 2 |
| Polman, CH | 2 |
| Hommes, OR | 6 |
| Valk, J | 6 |
| Takanashi, J | 1 |
| Sugita, K | 1 |
| Fujii, K | 1 |
| Takatsuna, Y | 1 |
| Niimi, H | 1 |
| Christiansen, AP | 1 |
| Wanscher, B | 2 |
| Henriksen, O | 3 |
| Campi, A | 5 |
| Filippi, M | 5 |
| Comi, G | 5 |
| Martinelli, V | 3 |
| Baratti, C | 1 |
| Rovaris, M | 1 |
| Scotti, G | 5 |
| Moreau, T | 1 |
| Thorpe, J | 1 |
| Miller, D | 2 |
| Moseley, I | 1 |
| Hale, G | 1 |
| Waldmann, H | 1 |
| Clayton, D | 1 |
| Wing, M | 1 |
| Scolding, N | 1 |
| Compston, A | 1 |
| Barkhof, F | 7 |
| Frequin, ST | 4 |
| Scheltens, P | 4 |
| Nauta, JJ | 3 |
| Bastianello, S | 3 |
| Pozzilli, C | 4 |
| D'Andrea, F | 1 |
| Millefiorini, E | 2 |
| Trojano, M | 2 |
| Morino, S | 1 |
| Gasperini, C | 3 |
| Bozzao, A | 2 |
| Gallucci, M | 1 |
| Andreula, C | 1 |
| Frank, JA | 6 |
| Stone, LA | 6 |
| Smith, ME | 2 |
| Albert, PS | 3 |
| Maloni, H | 7 |
| McFarland, HF | 6 |
| Davie, CA | 1 |
| Hawkins, CP | 1 |
| Barker, GJ | 2 |
| Brennan, A | 1 |
| Tofts, PS | 5 |
| Miller, DH | 5 |
| McDonald, WI | 10 |
| Goodkin, DE | 1 |
| Rudick, RA | 2 |
| Ross, JS | 1 |
| Katz, D | 1 |
| Taubenberger, JK | 1 |
| Cannella, B | 1 |
| McFarlin, DE | 2 |
| Raine, CS | 1 |
| Haas, DC | 1 |
| Kent, PF | 1 |
| Friedman, DI | 1 |
| De Coene, B | 1 |
| Hajnal, JV | 1 |
| Pennock, JM | 1 |
| Bydder, GM | 1 |
| Thompson, AJ | 8 |
| Kappos, L | 1 |
| Yousri, T | 1 |
| Berry, I | 1 |
| Appel, B | 1 |
| Mattioli, F | 1 |
| Cappa, SF | 1 |
| Cominelli, C | 1 |
| Capra, R | 4 |
| Marcianoc, N | 1 |
| Gasparotti, R | 4 |
| Karlik, SJ | 1 |
| Grant, EA | 1 |
| Lee, D | 1 |
| Noseworthy, JH | 1 |
| Martin, R | 2 |
| Armstrong, M | 1 |
| Colombo, B | 3 |
| Yousry, T | 3 |
| Canal, N | 1 |
| Birch, MK | 1 |
| Barbosa, S | 1 |
| Blumhardt, LD | 1 |
| O'Brien, C | 1 |
| Harding, SP | 1 |
| Kidd, D | 1 |
| Thorpe, JW | 1 |
| Kendall, BE | 6 |
| Lai, M | 1 |
| Hodgson, T | 1 |
| Gawne-Cain, M | 1 |
| Webb, S | 1 |
| MacManus, D | 2 |
| Kandziora, C | 1 |
| Voltz, R | 2 |
| Spuler, S | 2 |
| Bressi, S | 1 |
| Bolay, H | 1 |
| Karabudak, R | 1 |
| Tacal, T | 1 |
| Onol, B | 1 |
| Selekler, K | 1 |
| Saribaş, O | 1 |
| Sørensen, PS | 1 |
| Szpirt, W | 1 |
| Jensen, CV | 1 |
| Ravnborg, M | 1 |
| Christiansen, P | 2 |
| Schreiber, K | 1 |
| Nordenbo, A | 1 |
| Gerevini, S | 1 |
| Dousset, V | 1 |
| Prandini, F | 1 |
| Marcianò, N | 3 |
| Koudriavtseva, T | 2 |
| Galgani, S | 1 |
| Buttinelli, C | 2 |
| Perciaccante, G | 1 |
| Piazza, G | 1 |
| Bozzao, L | 2 |
| Fieschi, C | 2 |
| Bash, C | 1 |
| Stone, L | 1 |
| Petrella, J | 1 |
| McFarland, H | 2 |
| Di Biasi, C | 1 |
| Iannilli, M | 1 |
| Trasimeni, G | 1 |
| Argentino, C | 1 |
| Gualdi, GF | 1 |
| Avolio, C | 1 |
| Simone, IL | 1 |
| Defazio, G | 1 |
| Manzari, C | 1 |
| De Robertis, F | 1 |
| Calò, A | 1 |
| Livrea, P | 1 |
| Stüber, A | 1 |
| Scheller, A | 1 |
| Holler, E | 1 |
| Hartmann, M | 1 |
| Wick, M | 1 |
| Hohlfeld, R | 1 |
| Liebsch, R | 1 |
| Kornhuber, ME | 1 |
| Dietl, D | 1 |
| Gräfin von Einsiedel, H | 1 |
| Conrad, B | 1 |
| Tresley, RM | 1 |
| Fields, N | 1 |
| Calabresi, PA | 2 |
| Tranquill, LR | 1 |
| Dambrosia, JM | 1 |
| Bash, CN | 2 |
| Larsson, EM | 1 |
| Colosimo, M | 1 |
| Amatruda, A | 1 |
| Cioffi, RP | 1 |
| Lamers, K | 1 |
| van Geel, WJ | 1 |
| Einig, M | 1 |
| Higer, HP | 1 |
| Mauz, M | 1 |
| Ernst, JP | 1 |
| Paty, DW | 1 |
| Li, DK | 1 |
| Koopmans, R | 1 |
| Cotti Cometti, V | 1 |
| Vignolo, LA | 2 |
| Bettinzioli, M | 1 |
| Airó, P | 1 |
| Cattaneo, R | 1 |
| Moretti, R | 1 |
| Chiesa, A | 1 |
| Heijboer, RJ | 1 |
| Algra, PR | 1 |
| Frederiksen, JL | 2 |
| Mattingly, G | 1 |
| Baker, K | 1 |
| Zorumski, CF | 1 |
| Figiel, GS | 1 |
| Youl, B | 1 |
| Moore, S | 1 |
| Kingsley, D | 1 |
| Kendall, B | 1 |
| Feinstein, A | 1 |
| Burnham, JA | 1 |
| Wright, RR | 1 |
| Dreisbach, J | 1 |
| Murray, RS | 1 |
| Kermode, AG | 6 |
| Wicks, D | 1 |
| MacManus, DG | 5 |
| Kingsley, DP | 4 |
| Rüttinger, H | 2 |
| Rüttinger, P | 1 |
| Hermes, M | 2 |
| Barnes, D | 2 |
| Munro, PM | 1 |
| Youl, BD | 1 |
| Prineas, JW | 1 |
| Bronen, RA | 1 |
| Sze, G | 1 |
| Tofts, P | 1 |
| Moseley, IF | 4 |
| Rudge, P | 3 |
| Stubgaard, M | 1 |
| Jensen, M | 1 |
| Paulson, OB | 1 |
| du Boulay, EP | 1 |
| Bernardi, S | 1 |
| Fantozzi, LM | 1 |
| Johnson, G | 1 |
| Grossman, RI | 3 |
| Braffman, BH | 1 |
| Brorson, JR | 1 |
| Goldberg, HI | 1 |
| Silberberg, DH | 3 |
| Gonzalez-Scarano, F | 3 |
| Galetta, S | 2 |
| Atlas, SW | 2 |
| Gowin, W | 1 |
| Weihe, W | 1 |
| Appel, C | 1 |
| Mariss, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid[NCT03492255] | 49 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Significative difference between percentage of renal response (primary outcome) between the two study arms.) | |||
| Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.[NCT00270816] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI)[NCT00001248] | 3,750 participants (Anticipated) | Observational | 1992-07-23 | Recruiting | |||
| The Effect of Percutaneous Venoplasty on Muscular Function, Mobility and Fatigue of Multiple Sclerosis (MS) Patients With Chronic Cerebrospinal Venous Insufficiency (CCSVI).[NCT01555684] | 0 participants (Actual) | Interventional | 2012-04-30 | Withdrawn | |||
| The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis[NCT03193086] | 35 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pentetic acid and Multiple Sclerosis
| Article | Year |
|---|---|
[Magnetic resonance imaging of disseminated sclerosis].
Topics: Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Organometal | 1994 |
The use of brain magnetic resonance imaging in multiple sclerosis.
Topics: Brain; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis; | 1994 |
Magnetic resonance imaging in multiple sclerosis: an overview.
Topics: Brain; Diagnosis, Differential; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Multiple Sclero | 1992 |
Magnetic resonance imaging contrast agents: theory and application to the central nervous system.
Topics: Animals; Brain Diseases; Brain Neoplasms; Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonanc | 1990 |
7 trials available for pentetic acid and Multiple Sclerosis
| Article | Year |
|---|---|
[Clinical usefulness of MRI in acute phase of spinal multiple sclerosis--influence of high-dose steroid therapy in acute phase].
Topics: Acute Disease; Adolescent; Adult; Aged; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; | 1995 |
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.
Topics: Adolescent; Adult; Contrast Media; Double-Blind Method; Female; Gadolinium DTPA; Humans; Magnetic Re | 1994 |
Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.
Topics: Contrast Media; Dose-Response Relationship, Drug; Gadolinium; Gadolinium DTPA; Humans; Magnetic Reso | 1996 |
Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.
Topics: Adult; Autoimmune Diseases; Azathioprine; Contrast Media; Cross-Over Studies; Female; Gadolinium DTP | 1996 |
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Brain; Female; Gadolinium DTPA; Humans; Injections, Subcutaneous; Interferon beta | 1996 |
High-dose contrast-enhanced MRI in multiple sclerosis.
Topics: Adult; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Image En | 1996 |
Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
Topics: Adult; Biomarkers; Brain; Cell Adhesion Molecules, Neuronal; Cerebrospinal Fluid; Contrast Media; Dr | 1997 |
62 other studies available for pentetic acid and Multiple Sclerosis
| Article | Year |
|---|---|
Correlation of isotopic cisternographic patterns in multiple sclerosis with CSF IgG values.
Topics: Adult; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Female; Humans; Immunoglobulin G; Male; Mid | 1982 |
The evolution of multiple sclerosis lesions on serial MR.
Topics: Adult; Brain; Contrast Media; Drug Combinations; Female; Follow-Up Studies; Gadolinium DTPA; Humans; | 1995 |
In vivo characterization of the multiple sclerosis plaque by magnetic resonance imaging and spectroscopy.
Topics: Adult; Axons; Blood-Brain Barrier; Brain; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic | 1995 |
The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Drug Combinations; Female; Gadolinium DTPA; Humans; Magnetic Resonance | 1995 |
Optic neuritis with silent cerebral lesions: availability of FLAIR sequences.
Topics: Brain; Child; Contrast Media; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging | 1995 |
Acute transverse myelopathy: spinal and cranial MR study with clinical follow-up.
Topics: Acute Disease; Adolescent; Adult; Aged; Brain; Contrast Media; Diagnosis, Differential; Drug Combina | 1995 |
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.
Topics: Antigens, CD; Antigens, Neoplasm; Brain; CD52 Antigen; Contrast Media; Female; Gadolinium; Gadoliniu | 1994 |
Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Methylprednisolon | 1994 |
Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials.
Topics: Adult; Blood-Brain Barrier; Brain; Chronic Disease; Clinical Trials as Topic; Gadolinium DTPA; Human | 1994 |
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions.
Topics: Adult; Aspartic Acid; Creatine; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Magneti | 1994 |
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.
Topics: Adult; Brain; Cerebral Cortex; Chronic Disease; Contrast Media; Female; Gadolinium DTPA; HLA Antigen | 1993 |
Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area.
Topics: Adolescent; Cerebral Cortex; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Headache; H | 1993 |
Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Female; Follow-Up Studies; Gadolinium; Gadolinium DTPA; Humans; Infant | 1994 |
MRI of the brain stem using fluid attenuated inversion recivery pulse sequences.
Topics: Adult; Brain Diseases; Brain Neoplasms; Brain Stem; Cerebral Infarction; Cerebrospinal Fluid Shunts; | 1993 |
Database for serial magnetic resonance imaging in multiple sclerosis.
Topics: Brain; Contrast Media; Data Collection; Databases, Bibliographic; Follow-Up Studies; Gadolinium DTPA | 1993 |
Serial study of neuropsychological performance and gadolinium-enhanced MRI in MS.
Topics: Adult; Brain; Contrast Media; Disability Evaluation; Female; Gadolinium DTPA; Humans; Magnetic Reson | 1993 |
Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig.
Topics: Animals; Blood-Brain Barrier; Brain; Contrast Media; Encephalomyelitis, Autoimmune, Experimental; Ga | 1993 |
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
Topics: Adult; Brain; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Methylprednisolone; M | 1993 |
Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis.
Topics: Adult; Analysis of Variance; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Middle Aged; Multi | 1995 |
Retinal venous sheathing and the blood-retinal barrier in multiple sclerosis.
Topics: Adult; Blood-Retinal Barrier; Brain; Capillary Permeability; Contrast Media; Female; Fluorescein Ang | 1996 |
MRI dynamics of brain and spinal cord in progressive multiple sclerosis.
Topics: Atrophy; Brain; Contrast Media; Disabled Persons; Gadolinium DTPA; Humans; Longitudinal Studies; Mag | 1996 |
A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.
Topics: Adult; Blood-Brain Barrier; Contrast Media; Disabled Persons; Female; Gadolinium; Gadolinium DTPA; H | 1996 |
Balo's concentric sclerosis. Report of two patients with magnetic resonance imaging follow-up.
Topics: Adult; Brain Diseases; Contrast Media; Diffuse Cerebral Sclerosis of Schilder; Female; Follow-Up Stu | 1996 |
Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Dominance, Cerebral; Female; Gadolinium DTPA; Humans; Image Enhancemen | 1996 |
Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis.
Topics: Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Organometallic Compounds; P | 1996 |
Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Topics: Adjuvants, Immunologic; Adult; Brain; Contrast Media; Drug Combinations; Female; Gadolinium DTPA; Hu | 1996 |
Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings.
Topics: Adolescent; Adult; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gadolinium DTPA; Hu | 1996 |
Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: a serial analysis.
Topics: Adult; Antigens, CD; Brain; CD4-Positive T-Lymphocytes; Cell Adhesion Molecules; Cell Separation; Fe | 1996 |
Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity.
Topics: Adult; Contrast Media; Disease Progression; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imag | 1996 |
Blood-CSF barrier integrity in multiple sclerosis.
Topics: Adult; Blood-Brain Barrier; Capillary Permeability; Contrast Media; Female; Gadolinium DTPA; Humans; | 1996 |
Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials.
Topics: Adult; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contrast Media; Drug A | 1997 |
Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
Topics: Adjuvants, Immunologic; Adult; Blood-Brain Barrier; Brain; Female; Follow-Up Studies; Gadolinium DTP | 1997 |
Magnetic resonance imaging of the cervical and thoracic spine and the spinal cord. A study using a 0.3 T vertical magnetic field.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cervical Vertebrae; Child; Child, | 1992 |
A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Topics: Adult; Contrast Media; Disability Evaluation; Female; Gadolinium DTPA; Humans; Injections, Intraveno | 1992 |
[Intracranial tumor-like lesions in children and young adults with multiple sclerosis].
Topics: Adolescent; Adult; Brain; Brain Neoplasms; Child; Child, Preschool; Contrast Media; Diagnosis, Diffe | 1992 |
Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
Topics: Adult; Brain; Contrast Media; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Multi | 1992 |
MRI in monitoring the treatment of multiple sclerosis: concerted action guidelines.
Topics: Blood-Brain Barrier; Brain; Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Mul | 1992 |
Immunological and gadolinium-DTPA MRI evaluation of relapsing remitting multiple sclerosis.
Topics: Adult; Blood-Brain Barrier; CD4-CD8 Ratio; Contrast Media; Female; Gadolinium DTPA; Humans; Leukocyt | 1992 |
The value of brain magnetic resonance imaging in multiple sclerosis.
Topics: Brain; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Organometallic Compo | 1992 |
Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis.
Topics: Adult; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Scle | 1992 |
Inadvertent i.v. administration of gadopentetate dimeglumine during early pregnancy.
Topics: Adult; Drug Combinations; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; M | 1992 |
Gd-DTPA-enhanced lesions in the brain of patients with acute optic neuritis.
Topics: Adult; Blood-Brain Barrier; Brain; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonan | 1992 |
Multiple sclerosis and ECT: possible value of gadolinium-enhanced magnetic resonance scans for identifying high-risk patients.
Topics: Adult; Brain; Contrast Media; Depressive Disorder; Electroconvulsive Therapy; Female; Gadolinium DTP | 1992 |
Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.
Topics: Adult; Contrast Media; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Middl | 1992 |
Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis.
Topics: Adult; Blood-Brain Barrier; Brain; Capillary Permeability; Contrast Media; Dose-Response Relationshi | 1991 |
The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions.
Topics: Adult; Blood-Brain Barrier; Brain; Encephalomyelitis; Female; Gadolinium DTPA; Humans; Injections, I | 1991 |
Major differences in the dynamics of primary and secondary progressive multiple sclerosis.
Topics: Adult; Brain; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multip | 1991 |
[Cerebrospinal fluid IgG and the blood-brain barrier in multiple sclerosis. A new viewpoint].
Topics: Adult; Blood-Brain Barrier; Contrast Media; Female; Gadolinium DTPA; Humans; Immunoglobulin G; Immun | 1991 |
Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts.
Topics: Adult; Blood-Brain Barrier; Brain Diseases; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Hum | 1991 |
The longstanding MS lesion. A quantitative MRI and electron microscopic study.
Topics: Adult; Brain; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Microsc | 1991 |
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.
Topics: Adult; Blood-Brain Barrier; Brain; Contrast Media; Disability Evaluation; Female; Gadolinium DTPA; H | 1990 |
Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Contrast Media; Gadolinium; Gadolinium DTPA; Humans; Im | 1990 |
Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement.
Topics: Adolescent; Adult; Blood-Brain Barrier; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Humans; | 1990 |
Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis.
Topics: Adult; Brain; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imagin | 1990 |
[Magnetic resonance tomography with gadolinium DTPA in multiple sclerosis. Findings in initial manifestation and later disease stages].
Topics: Adult; Brain; Contrast Media; Diagnosis, Differential; Female; Gadolinium DTPA; Humans; Magnetic Res | 1990 |
Blood brain barrier permeability in multiple sclerosis using labelled DTPA with PET, CT and MRI.
Topics: Blood-Brain Barrier; Capillary Permeability; Contrast Media; Edetic Acid; Gadolinium DTPA; Humans; I | 1989 |
Pathogenesis of progressive multiple sclerosis.
Topics: Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Organometallic Compounds; P | 1989 |
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.
Topics: Adult; Blood-Brain Barrier; Brain; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Middle Aged; | 1988 |
Multiple sclerosis: serial study of gadolinium-enhanced MR imaging.
Topics: Adult; Aged; Blood-Brain Barrier; Brain; Contrast Media; Drug Combinations; Female; Gadolinium DTPA; | 1988 |
Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Topics: Adult; Aged; Brain; Contrast Media; Drug Combinations; Female; Gadolinium; Gadolinium DTPA; Humans; | 1987 |
Multiple sclerosis: gadolinium enhancement in MR imaging.
Topics: Adult; Aged; Contrast Media; Diatrizoate Meglumine; Female; Gadolinium; Humans; Magnetic Resonance S | 1986 |
[Magnetic resonance tomography of non-acute multiple sclerosis before and after use of a contrast medium (Gd-DTPA)].
Topics: Adult; Brain; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Spectr | 1986 |